NoneIncrease
Body weight
Insulin aspart → Body weight
Insulin aspart → Body weight
Evidence profile
NoneIncreaseWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Semaglutide improves glycemic control more than insulin aspart in type 2 diabetes
Key finding
HbA1c decreased by 1.5% points (16.6 mmol/mol).
This study compared once-weekly semaglutide to thrice-daily insulin aspart in adults with type 2 diabetes, revealing significant differences in HbA1c and body weight outcomes.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Some Concerns bias
Last updated July 5, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Once-weekly semaglutide, Thrice-daily insulin aspart
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
HbA1c
Comparator
Thrice-daily insulin aspart
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study compared once-weekly semaglutide to thrice-daily insulin aspart in adults with type 2 diabetes, revealing significant differences in HbA1c and body weight outcomes.
Clinical relevance
These findings are significant as they suggest that once-weekly semaglutide may offer a more effective treatment option for adults with type 2 diabetes, leading to better management of blood sugar levels and weight loss. This could improve patient adherence to treatment and overall health outcomes, reducing the risk of diabetes-related complications.
Keep in mind
The study did not report on long-term effects beyond the trial duration. Sample size and demographic diversity may limit generalizability. The study did not explore patient adherence to medication.
Published in
Journal Reference
Publication details and source links for this paper.
Monika K, Margit SK, Jack L, et al. Once-Weekly Semaglutide versus Thrice-Daily Insulin Aspart in Adults with Type 2 Diabetes: A Randomized Trial. Diabetes, Obesity & Metabolism. 2022;24(9):1788-1799. doi:10.1111/dom.14765
Save this study and add notes to your research library.
Main Effects
HbA1c decreased by 1.5% points (16.6 mmol/mol) with semaglutide, p-value 0.0001.
HbA1c decreased by 1.2% points (13.4 mmol/mol) with insulin aspart, p-value 0.0001.
Body weight decreased by 4.1 kg with semaglutide.
Body weight increased by 2.8 kg with insulin aspart.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin aspart, Semaglutide and Body weight, HbA1c, Severe hypoglycemia.
This study contributes evidence to
Primary intervention
Insulin aspart
Primary outcomes
- Body weight
- HbA1c
- Severe hypoglycemia
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
291
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
HbA1c
Insulin aspart → HbA1c
Insulin aspart → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
NoneNo Change
Severe hypoglycemia
Insulin aspart → Severe hypoglycemia
Insulin aspart → Severe hypoglycemia
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
NoneDecrease
Body weight
Semaglutide → Body weight
Semaglutide → Body weight
Evidence profile
NoneDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
HbA1c
Semaglutide → HbA1c
Semaglutide → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
NoneNo Change
Severe hypoglycemia
Semaglutide → Severe hypoglycemia
Semaglutide → Severe hypoglycemia
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Semaglutide reduced HbA1c by 1.5% points, significantly more than insulin aspart.
- Participants on semaglutide lost an average of 4.1 kg, while those on insulin gained weight.
- Both treatments had similar rates of severe hypoglycaemic episodes.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients requiring pharmacological management of blood sugar levels.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- The trial duration may not reflect long-term treatment outcomes.
- Further studies are needed to assess adherence and real-world effectiveness.
Between the Lines
- The study did not report on long-term effects beyond the trial duration.
- Sample size and demographic diversity may limit generalizability.
- The study did not explore patient adherence to medication.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
10 studies
outcome_hubMeasures Body Weight as a key outcome.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
10 results
All studies on Semaglutide
Intervention: Semaglutide
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
All studies measuring Body weight
Outcome: Body weight
10 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Moderate Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.8 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 66.2 | moderate positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Limited Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Hypoglycemia.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 43.2 | neutral | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Insulin aspart improve HbA1c?
Emerging Evidence
Insulin aspart appears to improve HbA1c.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 55.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesOral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.